Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway
Open Access
- 25 September 2021
- Vol. 24 (10) , 103173
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (Z01-BC006150)
- National Institutes of Health
This publication has 66 references indexed in Scilit:
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agentsProceedings of the National Academy of Sciences, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Systematic identification of genomic markers of drug sensitivity in cancer cellsNature, 2012
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitorsHaematologica, 2011
- Role of Interferon α (IFNα)-inducible Schlafen-5 in Regulation of Anchorage-independent Growth and Invasion of Malignant Melanoma CellsJournal of Biological Chemistry, 2010
- Transcriptional silencing of the ETS1 oncogene contributes to human granulocytic differentiationHaematologica, 2010
- Role of Schlafen 2 (SLFN2) in the Generation of Interferon α-induced Growth Inhibitory ResponsesJournal of Biological Chemistry, 2009
- Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaJournal of Experimental Medicine, 2008
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005